SAGE Therapeutics (SAGE) Stock Forecast & Price Target

Compare

935 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SAGE Analyst Ratings

Hold

1 Buy

13 Hold

1 Sell

Based on 15 analysts giving stock ratings to

SAGE

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SAGE Stock 12 Month Forecast

Average Price Target

$8.86

▼(-4.53%Downside)

Based on 15 Wall Street analysts offering 12 month price targets for SAGE Therapeutics in the last 3 months. The average price target is $8.86 with a high forecast of $12.00 and a low forecast of $5.00. The average price target represents a -4.53% change from the last price of $9.28.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","14":"$14","6.5":"$6.5","11.5":"$11.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,6.5,9,11.5,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.62,7.033846153846154,7.447692307692308,7.861538461538462,8.275384615384615,8.68923076923077,9.103076923076923,9.516923076923078,9.930769230769231,10.344615384615384,10.758461538461539,11.172307692307694,11.586153846153845,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.62,6.792307692307692,6.964615384615384,7.136923076923077,7.309230769230769,7.481538461538461,7.653846153846153,7.826153846153845,7.998461538461538,8.170769230769231,8.343076923076923,8.515384615384615,8.687692307692307,{"y":8.86,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.62,6.495384615384616,6.3707692307692305,6.246153846153846,6.121538461538462,5.996923076923077,5.872307692307692,5.747692307692308,5.623076923076923,5.498461538461538,5.373846153846154,5.249230769230769,5.124615384615384,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.28,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.11,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.03,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.76,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.96,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.05,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.79,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.43,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.25,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.3,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.86,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.48,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.62,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$12.00

Average Price Target$8.86

Lowest Price Target$5.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$9.5

Hold

2.37%

Upside

Reiterated

06/17/25

The overall stock score for SAGE is influenced primarily by its challenging financial performance, which presents significant risks. Despite some positive momentum in technical analysis and a promising earnings call focused on growth for ZURZUVAE, the negative valuation highlights persistent profitability concerns. The announced merger with Supernus Pharmaceuticals provides a positive outlook, but the existing financial issues weigh heavily on the overall score.

Joel BeattyRobert W. Baird

Robert W. Baird

$7→$9

Hold

-3.02%

Downside

Reiterated

06/20/25

Sage Therapeutics price target raised to $9 from $7 at BairdSage Therapeutics price target raised to $9 from $7 at Baird

Anupam RamaJ.P. Morgan

J.P. Morgan

$11→$8.5

Hold

-8.41%

Downside

Reiterated

06/20/25

J.P. Morgan Remains a Hold on SAGE Therapeutics (SAGE)

Joon LeeTruist Financial

Truist Financial

Hold

-3.02%

Downside

Reiterated

06/17/25

Truist Financial Reaffirms Their Hold Rating on SAGE Therapeutics (SAGE)

Douglas TsaoH.C. Wainwright

H.C. Wainwright

$12

Hold

29.31%

Upside

Reiterated

06/17/25

H.C. Wainwright Keeps Their Hold Rating on SAGE Therapeutics (SAGE)

Ritu BaralTD Cowen

TD Cowen

$9→$8.5

Hold

-8.41%

Downside

Reiterated

06/17/25

TD Cowen Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)

David AmsellemPiper Sandler

Piper Sandler

$9→$8.5

Hold

-8.41%

Downside

Downgraded

06/17/25

Sage Therapeutics downgraded to Neutral from Overweight at Piper SandlerSage Therapeutics downgraded to Neutral from Overweight at Piper Sandler

George FarmerScotiabank

Scotiabank

$12

Buy

29.31%

Upside

Reiterated

06/17/25

Scotiabank Sticks to Its Buy Rating for SAGE Therapeutics (SAGE)

Vikram PurohitMorgan Stanley

Morgan Stanley

$9→$8.5

Hold

-8.41%

Downside

Reiterated

06/17/25

Hold Rating on SAGE Therapeutics Amid Acquisition Offer and CVR Uncertainties

Laura ChicoWedbush

Wedbush

$6→$8.5

Hold

-8.41%

Downside

Reiterated

06/16/25

Wedbush Keeps Their Hold Rating on SAGE Therapeutics (SAGE)

Sumant KulkarniCanaccord Genuity

Canaccord Genuity

$8→$8.5

Hold

-8.41%

Downside

Reiterated

06/16/25

Hold Rating on SAGE Therapeutics Amid Uncertainty and Acquisition Developments

Brian AbrahamsRBC Capital

RBC Capital

$7→$9

Hold

-3.02%

Downside

Reiterated

06/16/25

Analysts' Top Healthcare Picks: Surgery Partners (SGRY), SAGE Therapeutics (SAGE)

Tazeen AhmadBank of America Securities

Bank of America Securities

Sell

-46.12%

Downside

Reiterated

05/19/25

Bank of America Securities Sticks to Their Sell Rating for SAGE Therapeutics (SAGE)

Ami FadiaNeedham

Needham

―

Hold

―

Reiterated

04/30/25

Cautious Hold Rating on SAGE Therapeutics Amid Uncertain Growth Prospects

Marc GoodmanLeerink Partners

Leerink Partners

Hold

-13.79%

Downside

Reiterated

04/29/25

SAGE Therapeutics: Hold Rating Maintained Amid Steady Growth and Strategic Uncertainties

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$9.5

Hold

2.37%

Upside

Reiterated

06/17/25

Joel BeattyRobert W. Baird

Robert W. Baird

$7→$9

Hold

-3.02%

Downside

Reiterated

06/20/25

Sage Therapeutics price target raised to $9 from $7 at BairdSage Therapeutics price target raised to $9 from $7 at Baird

Anupam RamaJ.P. Morgan

J.P. Morgan

$11→$8.5

Hold

-8.41%

Downside

Reiterated

06/20/25

J.P. Morgan Remains a Hold on SAGE Therapeutics (SAGE)

Joon LeeTruist Financial

Truist Financial

Hold

-3.02%

Downside

Reiterated

06/17/25

Truist Financial Reaffirms Their Hold Rating on SAGE Therapeutics (SAGE)

Douglas TsaoH.C. Wainwright

H.C. Wainwright

$12

Hold

29.31%

Upside

Reiterated

06/17/25

H.C. Wainwright Keeps Their Hold Rating on SAGE Therapeutics (SAGE)

Ritu BaralTD Cowen

TD Cowen

$9→$8.5

Hold

-8.41%

Downside

Reiterated

06/17/25

TD Cowen Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)

David AmsellemPiper Sandler

Piper Sandler

$9→$8.5

Hold

-8.41%

Downside

Downgraded

06/17/25

Sage Therapeutics downgraded to Neutral from Overweight at Piper SandlerSage Therapeutics downgraded to Neutral from Overweight at Piper Sandler

George FarmerScotiabank

Scotiabank

$12

Buy

29.31%

Upside

Reiterated

06/17/25

Scotiabank Sticks to Its Buy Rating for SAGE Therapeutics (SAGE)

Vikram PurohitMorgan Stanley

Morgan Stanley

$9→$8.5

Hold

-8.41%

Downside

Reiterated

06/17/25

Hold Rating on SAGE Therapeutics Amid Acquisition Offer and CVR Uncertainties

Laura ChicoWedbush

Wedbush

$6→$8.5

Hold

-8.41%

Downside

Reiterated

06/16/25

Wedbush Keeps Their Hold Rating on SAGE Therapeutics (SAGE)

Sumant KulkarniCanaccord Genuity

Canaccord Genuity

$8→$8.5

Hold

-8.41%

Downside

Reiterated

06/16/25

Hold Rating on SAGE Therapeutics Amid Uncertainty and Acquisition Developments

Brian AbrahamsRBC Capital

RBC Capital

$7→$9

Hold

-3.02%

Downside

Reiterated

06/16/25

Analysts' Top Healthcare Picks: Surgery Partners (SGRY), SAGE Therapeutics (SAGE)

Tazeen AhmadBank of America Securities

Bank of America Securities

Sell

-46.12%

Downside

Reiterated

05/19/25

Bank of America Securities Sticks to Their Sell Rating for SAGE Therapeutics (SAGE)

Ami FadiaNeedham

Needham

―

Hold

―

Reiterated

04/30/25

Cautious Hold Rating on SAGE Therapeutics Amid Uncertain Growth Prospects

Marc GoodmanLeerink Partners

Leerink Partners

Hold

-13.79%

Downside

Reiterated

04/29/25

SAGE Therapeutics: Hold Rating Maintained Amid Steady Growth and Strategic Uncertainties

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering SAGE Therapeutics

1 Month

xxx

Success Rate

11/20 ratings generated profit

Average Return

-1.56%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 55.00% of your transactions generating a profit, with an average return of -1.56% per trade.

3 Months

xxx

Success Rate

13/20 ratings generated profit

Average Return

+0.39%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 65.00% of your transactions generating a profit, with an average return of +0.39% per trade.

1 Year

Tazeen AhmadBank of America Securities

Success Rate

8/20 ratings generated profit

Average Return

-13.11%

reiterated a sell rating last month

Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -13.11% per trade.

2 Years

xxx

Success Rate

5/20 ratings generated profit

Average Return

-30.40%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of -30.40% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SAGE Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SAGE has received 3 Buy Ratings, 24 Hold Ratings, and 1 Sell Ratings. SAGE average Analyst price target in the past 3 months is 8.86.

Each month's total comprises the sum of three months' worth of ratings.

SAGE Financial Forecast

SAGE Earnings Forecast

Next quarter’s earnings estimate for SAGE is -$0.94 with a range of -$1.02 to -$0.80. The previous quarter’s EPS was -$1.01. SAGE beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.17% of the time in the same period. In the last calendar year SAGE has Outperformed its overall industry.

SAGE Sales Forecast

Next quarter’s sales forecast for SAGE is $16.74M with a range of $15.00M to $19.60M. The previous quarter’s sales results were $14.06M. SAGE beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.52% of the time in the same period. In the last calendar year SAGE has Outperformed its overall industry.

SAGE Stock Forecast FAQ

What is SAGE’s average 12-month price target, according to analysts?

Based on analyst ratings, SAGE Therapeutics’s 12-month average price target is 8.86.

What is SAGE’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for SAGE, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SAGE a Buy, Sell or Hold?

SAGE Therapeutics has a consensus rating of Hold which is based on 1 buy ratings, 13 hold ratings and 1 sell ratings.

What is SAGE Therapeutics’s price target?

The average price target for SAGE Therapeutics is 8.86. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $12.00 ,the lowest forecast is $5.00. The average price target represents -4.53% Decrease from the current price of $9.28.

What do analysts say about SAGE Therapeutics?

SAGE Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of SAGE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

SAGE Therapeutics (SAGE) Stock Forecast & Price Target

SAGE Analyst Ratings

SAGE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering SAGE Therapeutics

SAGE Analyst Recommendation Trends

SAGE Financial Forecast

SAGE Earnings Forecast

SAGE Sales Forecast

SAGE Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts